Screener
Corvus Pharmaceuticals CRVS Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-057100
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Proceeds from issuance of common stock in connection with follow-on public offering, net | 189,407 | — |
| Proceeds from exercise of common stock options | 1,339 | 279 |
| Net cash provided by financing activities | 190,746 | 279 |
| Net increase (decrease) in cash and cash equivalents | 35,526 | (3,741) |
| Cash and cash equivalents at beginning of the period | 4,576 | 8,740 |
| Cash and cash equivalents at end of the period | $40,102 | $4,999 |
| Supplemental disclosures of cash flow information | ||
| Offering costs recorded to additional paid-in-capital but not paid | $553 | — |
Item 1. Financial Statements (unaudited)
FAQ
- What is Corvus Pharmaceuticals's net change in cash?
- Corvus Pharmaceuticals (CRVS) reported net change in cash of $35.53M in Q1 2026.
- How has Corvus Pharmaceuticals's net change in cash changed year-over-year?
- Corvus Pharmaceuticals's net change in cash increased by 1049.6% year-over-year, from -$3.74M to $35.53M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Corvus Pharmaceuticals's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude